

FDA-APPROVED OVARIAN CANCER TREATMENTS

Generic	Brand	Strength	Form	Usual Dose
ALKYLATING AGENT				
carboplatin	—	10mg/mL	soln for IV infusion	<i>Advanced ovarian cancer (previously untreated):</i> 300mg/m ² on Day 1 every 4wks for 6 cycles. <i>Recurrent ovarian cancer:</i> 360mg/m ² on Day 1 every 4wks
cisplatin	—	1mg/mL	soln for IV infusion after dilution	
		50mg/vial	pwd for IV infusion after reconstitution and dilution	
cyclophosphamide	—	25mg, 50mg	tabs	1–5mg/kg/day
		500mg, 1g, 2g	pwd for inj after reconstitution	40–50mg/kg in divided doses over 2–5 days or 10–15mg/kg every 7–10 days or 3–5mg/kg twice weekly
melphalan	—	2mg	scored tabs	0.2mg/kg/day for 5 days; repeat every 4–5wks
thiotepa	—	15mg	pwd for IV, intravesical, or intracavitary administration after reconstitution	0.3–0.4mg/kg IV once every 1–4wks
ANTIBIOTICS (CYTOTOXIC)				
doxorubicin	—	10mg, 20mg, 50mg	pwd for IV inj after reconstitution	<i>Monotherapy:</i> 60–75mg/m ² every 21 days. <i>Combination therapy:</i> 40–60mg/m ² every 21 to 28 days
		2mg/mL	soln for IV inj	
doxorubicin (liposomal)	Doxil	2mg/mL	dispersion for IV infusion after dilution	50mg/m ² once every 4wks; continue for ≥4 cycles as tolerated. Initial rate: 1mg/min; may increase rate to complete infusion over 1hr if no infusion reactions occur.
ANTIMETABOLITE				
gemcitabine	—	200mg, 1g, 2g	pwd for IV infusion after reconstitution	1000mg/m ² on Days 1 and 8 of each 21-day cycle; give with carboplatin AUC 4 administered on Day 1 after gemcitabine
	Infugem	1200mg/120mL, 1300mg/130mL, 1400mg/140mL, 1500mg/150mL, 1600mg/160mL, 1700mg/170mL, 1800mg/180mL, 1900mg/190mL, 2000mg/200mL, 2200mg/220mL	soln for IV infusion	
ANTIMICROTUBULE AGENTS				
paclitaxel	—	6mg/mL	soln for IV infusion after dilution	<i>Previously untreated ovarian cancer:</i> 175mg/m ² IV over 3hrs + cisplatin; or 135mg/m ² IV over 24hrs + cisplatin; repeat every 3wks. <i>Previously treated ovarian cancer:</i> 135mg/m ² or 175mg/m ² over 3hrs every 3wks
POLY (ADP-RIBOSE) POLYMERASE INHIBITOR				
niraparib	Zejula	100mg	caps	<i>First-line maintenance of advanced ovarian cancer:</i> start within 12wks after most recent platinum-containing regimen; (patients <77kg or with platelets <150000/μL): 200mg once daily; (patients ≥77kg and platelets ≥150000/μL): 300mg once daily. <i>Maintenance of recurrent ovarian cancer:</i> start within 8wks after most recent platinum-containing regimen; 300mg once daily. <i>All:</i> continue until disease progression or unacceptable toxicity.
olaparib	Lynparza	100mg, 150mg	tabs	300mg twice daily. <i>First-line maintenance of BRCA-mutated or HRD-positive advanced ovarian:</i> continue until disease progression, unacceptable toxicity, or completion of 2yrs of treatment. Discontinue if complete response at 2yrs; may treat beyond 2yrs in those with evidence of disease if provider can derive further benefit from continuous treatment. <i>Maintenance of recurrent ovarian or germline BRCA-mutated advanced ovarian:</i> continue until disease progression or unacceptable toxicity. <i>In combination with bevacizumab:</i> give bevacizumab (15mg/kg every 3wks) for total of 15mos (see full labeling).
rucaparib	Rubraca	200mg, 250mg, 300mg	tabs	<i>Recurrent epithelial ovarian cancer:</i> 600mg twice daily until disease progression or unacceptable toxicity.
TOPOISOMERASE INHIBITOR				
topotecan	Hycamtin	4mg	pwd for IV infusion after reconstitution and dilution	1.5mg/m ² daily for 5 consecutive days starting on Day 1 of a 21-day cycle
VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) INHIBITOR				
bevacizumab	Avastin	100mg, 400mg	soln for IV infusion after dilution	<i>Recurrent ovarian cancer (platinum-resistant):</i> 10mg/kg every 2wks with either paclitaxel, pegylated liposomal doxorubicin, or topotecan (weekly); or, 15mg/kg every 3wks with topotecan (every 3wks); <i>(platinum-sensitive):</i> 15mg/kg every 3wks with carboplatin/paclitaxel for 6 cycles and up to 8 cycles or carboplatin/gemcitabine for 6 cycles and up to 10 cycles; followed by bevacizumab 15mg/kg every 3wks as a single agent until disease progression. <i>Stage III/IV ovarian cancer:</i> 15mg/kg every 3wks with carboplatin/paclitaxel for up to 6 cycles; followed by bevacizumab 15mg/kg every 3wks as a single agent, for a total of up to 22 cycles or until disease progression, whichever occurs first.
bevacizumab-awwb	Mvasi	100mg, 400mg	soln for IV infusion after dilution	
bevacizumab-bvzr	Zirabev	100mg, 400mg	soln for IV infusion after dilution	
bevacizumab-maly	Alymsys	100mg, 400mg	soln for IV infusion after dilution	<i>Recurrent epithelial ovarian cancer (platinum-resistant):</i> 10mg/kg every 2wks with either paclitaxel, pegylated liposomal doxorubicin, or topotecan (weekly); or, 15mg/kg every 3wks with topotecan (every 3wks).

NOTES

Not an inclusive list of medications and/or doses. Please see drug monograph at www.eMPR.com and/or contact company for full drug labeling.

(Rev. 11/2022)